• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Vaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/7/25 4:03:56 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCVX alert in real time by email
    pcvx-20250507
    0001649094FALSE00016490942025-05-072025-05-07

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    _____________________________________________
    FORM 8-K
    _____________________________________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 7, 2025
    _____________________________________________
    Vaxcyte, Inc.
    (Exact name of Registrant as Specified in Its Charter)
    _____________________________________________
    Delaware01-3932346-4233385
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)(IRS Employer
    Identification No.)
    825 Industrial Road
    Suite 300
    San Carlos , California
     94070
    (Address of Principal Executive Offices)(Zip Code)
    Registrant’s Telephone Number, Including Area Code: (650) 837-0111
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
    _____________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    o
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    o
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    o
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    o
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class
    Trading
    Symbol(s)
    Name of each exchange on which registered
    Common Stock, $0.001 par value per sharePCVXThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 2.02 Results of Operations and Financial Condition.
    On May 7, 2025, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.
    The information in this Item 2.02 and Item 9.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
    Item 9.01 Financial Statements and Exhibits.
    (d)Exhibits
    Exhibit
    Number
    Description
    99.1
    Press Release of Vaxcyte, Inc., dated May 7, 2025
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
    VAXCYTE, INC.
    Date:May 7, 2025By: /s/ Andrew Guggenhime
    Andrew Guggenhime
    President and Chief Financial Officer

    Get the next $PCVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PCVX

    DatePrice TargetRatingAnalyst
    4/22/2025Overweight
    Cantor Fitzgerald
    12/20/2024$135.00Buy
    Goldman
    12/7/2023$69.00Buy
    Mizuho
    4/18/2023Outperform
    TD Cowen
    1/3/2023$52.00 → $58.00Buy
    Needham
    12/15/2022$66.00Buy
    Guggenheim
    11/17/2022$69.00Buy
    BTIG Research
    12/29/2021$50.00Buy
    Jefferies
    More analyst ratings

    $PCVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/14/24 5:46:11 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/14/24 2:53:06 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/12/24 10:34:18 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Brandicourt Olivier

      4 - Vaxcyte, Inc. (0001649094) (Issuer)

      5/2/25 4:28:47 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Brandicourt Olivier claimed no ownership of stock in the company (SEC Form 3)

      3 - Vaxcyte, Inc. (0001649094) (Issuer)

      5/2/25 4:27:02 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Dhaliwal Harpreet S. claimed ownership of 36,083 shares (SEC Form 3)

      3 - Vaxcyte, Inc. (0001649094) (Issuer)

      4/25/25 4:13:50 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    SEC Filings

    See more

    $PCVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $PCVX
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 10-Q filed by Vaxcyte Inc.

      10-Q - Vaxcyte, Inc. (0001649094) (Filer)

      5/7/25 4:23:38 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vaxcyte, Inc. (0001649094) (Filer)

      5/7/25 4:03:56 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.

      SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      5/7/25 10:56:23 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Vaxcyte

      Cantor Fitzgerald initiated coverage of Vaxcyte with a rating of Overweight

      4/22/25 7:35:12 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Vaxcyte with a new price target

      Goldman initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $135.00

      12/20/24 7:47:04 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on Vaxcyte with a new price target

      Mizuho initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $69.00

      12/7/23 7:01:04 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

      SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

      5/1/25 8:00:29 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints John Furey to Board of Directors

      SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. "We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24

      7/2/24 8:30:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints Whitney Jones as Chief People Officer

      -- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte's human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement. "At Vaxcyte, we are proud to cultivate a culture that values coll

      1/16/24 4:01:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

      -- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later -- -- Company Expects to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Announced VAX-XL, Third-Generation Pneumococcal Conjugate Vaccine Candidate Desig

      5/7/25 4:01:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

      SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

      5/1/25 8:00:29 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

      -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

      3/31/25 7:00:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Financials

    Live finance-specific insights

    See more
    • Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

      -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

      3/31/25 7:00:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

      SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants. To participate in the conference call, p

      3/30/25 5:00:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

      SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVXQ424. A live webcast

      2/12/25 4:05:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care